Last reviewed 2026-04-22 · How we verify

BAT5906 injection

BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.

BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).

At a glance

Mechanism of action

BAT5906 functions as a bispecific monoclonal antibody designed to target dual immune pathways, likely involving PD-1 and LAG-3 or similar checkpoint molecules. By blocking inhibitory signals on T cells through multiple mechanisms simultaneously, the drug aims to achieve greater immune activation and tumor control compared to single-checkpoint inhibitors.

Approved indications

• Advanced or metastatic solid tumors (Phase 3 development)

Common side effects

• Immune-related adverse events (irAEs)
• Fatigue
• Diarrhea
• Rash

Key clinical trials

• Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (PHASE3)
• Clinical Study of the Safety and Efficacy of BAT5906 Injection (PHASE1, PHASE2)
• Clinical Study on the Efficacy and Safety of BAT5906 Injection (PHASE2)
• A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BAT5906 injection CI brief — competitive landscape report
• BAT5906 injection updates RSS · CI watch RSS
• Bio-Thera Solutions portfolio CI